Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Nov. 14, 2019
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Trading Symbol	TTOO
Entity Registrant Name	T2 Biosystems, Inc.
Entity Central Index Key	0001492674
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-36571
Entity Tax Identification Number	20-4827488
Entity Address, Address Line One	101 Hartwell Avenue
Entity Address, City or Town	Lexington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02421
City Area Code	781
Local Phone Number	761-4646
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.001
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		46,679,163

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 16,213	$ 50,805
Accounts receivable	1,573	1,786
Inventories	4,110	2,677
Prepaid expenses and other current assets	1,917	1,340
Total current assets	23,813	56,608
Property and equipment, net	6,314	7,315
Operating lease right-of-use assets	3,740
Restricted cash	180	180
Other assets	206	206
Total assets	34,253	64,309
Current liabilities:
Notes payable	42,258	42,373
Accounts payable	3,427	744
Accrued expenses and other current liabilities	8,800	6,073
Derivative liability	2,603	2,142
Deferred revenue	610	697
Current portion of lease incentives		268
Total current liabilities	57,698	52,297
Lease incentives, net of current portion		492
Operating lease liabilities, net of current portion	2,390
Deferred revenue, net of current portion	77	133
Commitments and contingencies (see Note 13)
Stockholders’ (deficit) equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2019 and December 31, 2018
Common stock, $0.001 par value; 200,000,000 shares authorized; 46,678,746 and 44,175,441 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	45	44
Additional paid-in capital	336,179	328,514
Accumulated deficit	(362,136)	(317,171)
Total stockholders’ (deficit) equity	(25,912)	11,387
Total liabilities and stockholders’ (deficit) equity	$ 34,253	$ 64,309

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	46,678,746	46,678,746
Common stock, shares outstanding	44,175,441	44,175,441

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue:
Total revenue	$ 1,677	$ 2,466	$ 5,266	$ 8,708
Costs and expenses:
Research and development	4,098	2,725	12,047	11,193
Selling, general and administrative	5,981	5,873	19,756	19,238
Total costs and expenses	14,023	11,640	44,956	40,204
Loss from operations	(12,346)	(9,174)	(39,690)	(31,496)
Interest expense, net	(1,876)	(1,836)	(5,658)	(4,910)
Other income, net	51	243	383	402
Net loss and comprehensive loss	$ (14,171)	$ (10,767)	$ (44,965)	$ (36,004)
Net loss per share — basic and diluted	$ (0.31)	$ (0.25)	$ (1.01)	$ (0.91)
Weighted-average number of common shares used in computing net loss per share — basic and diluted	45,413,215	43,762,551	44,711,463	39,363,294
Product [Member]
Revenue:
Total revenue	$ 1,177	$ 1,218	$ 3,765	$ 3,486
Costs and expenses:
Cost of product revenue	3,944	3,042	13,153	9,773
Research [Member]
Revenue:
Total revenue	56	$ 1,248	269	$ 5,222
Contribution [Member]
Revenue:
Total revenue	$ 444		$ 1,232

Condensed Consolidated Statements Stockholders' (Deficit) Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Common Stock [Member] Purchase Agreement [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2017	$ 1,340	$ 36		$ 267,421	$ (266,117)
Balance (in shares) at Dec. 31, 2017		35,948,900
Stock-based compensation expense	1,381			1,381
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan	5			5
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)		70,983
Prior year accumulated deficit adjustment from ASC 606 implementation	99				99
Net loss	(12,913)				(12,913)
Balance at Mar. 31, 2018	(10,088)	$ 36		268,807	(278,931)
Balance (in shares) at Mar. 31, 2018		36,019,883
Balance at Dec. 31, 2017	1,340	$ 36		267,421	(266,117)
Balance (in shares) at Dec. 31, 2017		35,948,900
Net loss	(36,004)
Balance at Sep. 30, 2018	23,767	$ 44		325,745	(302,022)
Balance (in shares) at Sep. 30, 2018		44,038,754
Balance at Mar. 31, 2018	(10,088)	$ 36		268,807	(278,931)
Balance (in shares) at Mar. 31, 2018		36,019,883
Stock-based compensation expense	3,898			3,898
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan	1,119			1,119
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)		382,114
Share issuance (in shares)		55,414
Issuance of common stock from secondary offering, net	49,378	$ 7		49,371
Issuance of common stock (in shares)		7,015,000
Net loss	(12,324)				(12,324)
Balance at Jun. 30, 2018	31,983	$ 43		323,195	(291,255)
Balance (in shares) at Jun. 30, 2018		43,472,411
Stock-based compensation expense	2,208			2,208
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan	484	$ 1		483
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)		566,343
Issuance of common stock from secondary offering, net	(141)			(141)
Net loss	(10,767)				(10,767)
Balance at Sep. 30, 2018	23,767	$ 44		325,745	(302,022)
Balance (in shares) at Sep. 30, 2018		44,038,754
Balance at Dec. 31, 2018	$ 11,387	$ 44		328,514	(317,171)
Balance (in shares) at Dec. 31, 2018	46,678,746	44,175,441
Stock-based compensation expense	$ 2,033			2,033
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)		163,802
Change in fair value of warrants upon modification	147			147
Net loss	(15,147)				(15,147)
Balance at Mar. 31, 2019	(1,580)	$ 44		330,694	(332,318)
Balance (in shares) at Mar. 31, 2019		44,339,243
Balance at Dec. 31, 2018	$ 11,387	$ 44		328,514	(317,171)
Balance (in shares) at Dec. 31, 2018	46,678,746	44,175,441
Net loss	$ (44,965)
Balance at Sep. 30, 2019	$ (25,912)	$ 45		336,179	(362,136)
Balance (in shares) at Sep. 30, 2019	46,678,746	46,678,746
Balance at Mar. 31, 2019	$ (1,580)	$ 44		330,694	(332,318)
Balance (in shares) at Mar. 31, 2019		44,339,243
Stock-based compensation expense	1,277			1,277
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan	330			330
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)		196,329
Net loss	(15,647)				(15,647)
Balance at Jun. 30, 2019	(15,620)	$ 44		332,301	(347,965)
Balance (in shares) at Jun. 30, 2019		44,535,572
Stock-based compensation expense	1,165			1,165
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan	53			53
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)		50,438
Issuance of common stock from secondary offering, net	1,884	$ 1		1,883
Issuance of common stock (in shares)		1,679,387	413,349
Change in fair value of warrants upon modification	117			117
Issuance of warrants	660			660
Net loss	(14,171)				(14,171)
Balance at Sep. 30, 2019	$ (25,912)	$ 45		$ 336,179	$ (362,136)
Balance (in shares) at Sep. 30, 2019	46,678,746	46,678,746

Condensed Consolidated Statement of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities
Net loss	$ (44,965)	$ (36,004)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,694	1,862
Amortization of operating lease right-of-use assets	1,065
Stock-based compensation expense	4,475	7,487
Change in fair value of derivative instrument	461	(175)
Loss on disposal of property and equipment	(3)	18
Impairment of property and equipment		173
Non-cash interest expense	1,763	1,658
Deferred rent		(162)
Changes in operating assets and liabilities:
Accounts receivable	213	(1,267)
Prepaid expenses and other assets	(577)	(1,254)
Inventories	(1,464)	(1,191)
Accounts payable	2,683	(40)
Accrued expenses and other liabilities	1,250	(771)
Deferred revenue	(143)	(784)
Operating lease liabilities	(1,694)
Net cash used in operating activities	(35,242)	(30,450)
Cash flows from investing activities
Purchases and manufacture of property and equipment	(735)	(950)
Net cash used in investing activities	(735)	(950)
Cash flows from financing activities
Proceeds from issuance of common stock and stock option exercises, net	383	1,604
Proceeds from issuance of common stock in public offering, net of offering costs	1,884	49,236
Principal repayments of finance leases	(882)	(1,094)
Net cash provided by financing activities	1,385	49,746
Net (decrease) increase in cash, cash equivalents and restricted cash	(34,592)	18,346
Cash, cash equivalents and restricted cash at beginning of period	50,985	42,059
Cash, cash equivalents and restricted cash at end of period	16,393	60,405
Supplemental disclosures of cash flow information
Cash paid for interest	3,435	2,859
Supplemental disclosures of noncash activities
Transfer of T2 owned instruments and components to (from) inventory	31	802
Change in fair value of warrants issued and modified	924
Right-of-use assets obtained in exchange for new operating lease liabilities	4,805
Purchases of property and equipment included in accounts payable and accrued expenses	$ 43	$ 109

Nature of Business

9 Months Ended

Sep. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Nature of Business

1. Nature of Business

T2 Biosystems, Inc. (the “Company”) was incorporated on April 27, 2006 as a Delaware corporation with operations based in Lexington, Massachusetts. The Company is an in vitro diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company is using its T2 Magnetic Resonance technology (“T2MR”) to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (“CFU/mL”). The Company’s initial development efforts target sepsis and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics. On September 22, 2014, the Company received market clearance from the U.S. Food and Drug Administration (“FDA”) for its first two products, the T2Dx Instrument (the “T2Dx”) and T2Candida Panel (“T2Candida”). On May 24, 2018, the Company received market clearance from the FDA for its T2Bacteria Panel (“T2Bacteria”). On February 6, 2019, the FDA granted the Company’s T2Resistance Panel designation as a Breakthrough Device. On August 2, 2019, the Center for Medicare & Medicaid Services (CMS) granted approval for a New Technology Add-on Payment for the T2Bacteria Panel for fiscal year 2020.

The Company has devoted substantially all of its efforts to research and development, business planning, recruiting management and technical staff, acquiring operating assets, raising capital, and, most recently, the commercialization and improvement of its existing products.

Liquidity and Going Concern

At September 30, 2019, the Company had cash and cash equivalents of $16.2 million and an accumulated deficit of $362.1 million. The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through its August 2014 initial public offering, its December 2015 public offering, its September 2016 private investment in public equity (“PIPE”) financing, its September 2017 public offering, its June 2018 public offering, its July 2019 establishment of an Equity Distribution Agreement and Equity Purchase Agreement, private placements of redeemable convertible preferred stock and debt financing arrangements.

The Company is subject to a number of risks similar to other newly commercial life science companies, including, but not limited to commercially launching the Company’s products, development and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital.

Having obtained authorization from the FDA to market the T2Dx, T2Candida, and T2Bacteria, the Company has incurred significant commercialization expenses related to product sales, marketing, manufacturing and distribution. The Company may seek to fund its operations through public equity, private equity or debt financings, as well as other sources. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms, or at all. The Company’s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company’s business, results of operations, financial condition and the Company’s ability to develop and commercialize T2Dx, T2Candida, T2Bacteria and other product candidates.

Pursuant to the requirements of Accounting Standards Codification (“ASC”) 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.

Management believes that its existing cash and cash equivalents at September 30, 2019, along with funding available through our Equity Distribution Agreement (the “Sales Agreement”) with Canaccord Genuity LLC, as agent (“Canaccord”) and our Purchase Agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”) (Note 7), will be sufficient to allow us to fund our current operating plan at least a year from issuance of these financial statements. However, because certain elements of our operating plan are outside of our control, including our ability to sell shares under the Sales Agreement and the Purchase Agreement, they cannot be considered probable. Under ASC 205-40, the future receipt of potential funding from the Company’s Co-Development partners and other resources cannot be considered probable at this time because none of the plans are entirely within the Company’s control. In addition, the Company is required to maintain a minimum cash balance under its Term Loan Agreement with CRG Servicing LLC (“CRG”) (Note 6).

These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include raising additional funding, earning milestone payments pursuant to the Company’s Co- Development agreements, delaying certain research projects and capital expenditures and eliminating certain future operating expenses in order to fund operations at reduced levels for the Company to continue as a going concern for a period of twelve months from the date the financial statements are issued. Management has concluded the likelihood that its plan to obtain sufficient funding from one or more of these sources or adequately reduce expenditures will be successful, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for a period of at least twelve months from the date of issuance of these condensed consolidated financial statements.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The Company’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as defined in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The Company’s condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, T2 Biosystems Securities Corporation. All intercompany balances and transactions have been eliminated.

Unaudited Interim Financial Information

Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

The accompanying interim condensed consolidated balance sheet as of September 30, 2019, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2019 and 2018, the condensed consolidated statements of stockholders’ equity (deficit) for the nine months ended September 30, 2019 and 2018, the condensed consolidated statements of cash flows for the nine months ended September 30, 2019 and 2018 and the related financial data and other information disclosed in these notes are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of September 30, 2019, and the results of its operations for the three and nine months ended September 30, 2019 and 2018 and its cash flows for the nine months ended September 30, 2019 and 2018. The results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019, any other interim periods, or any future year or period.

Segment Information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment, which is the business of developing and, upon regulatory clearance, commercializing its diagnostic products aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.

Geographic Information

The Company sells its products domestically and internationally. For the three and nine months ended September 30, 2019, there were no international customers that represented greater than 10% of total revenue. For the three months ended September 30, 2018, there was one international customer that represented greater than 10% of total revenue. For the nine months ended September 30, 2018, there were no international customers that represented greater than 10% of total revenue. Total international sales were approximately $0.6 million or 36% of total revenue and $0.6 million or 25% of total revenue for the three months ended September 30, 2019 and 2018, respectively. Total international sales were approximately $1.8 million or 34% of total revenue and $1.4 million or 16% of total revenue for the nine months ended September 30, 2019 and 2018, respectively.

As of September 30, 2019 and December 31, 2018, the Company had outstanding receivables of $0.5 million and $0.9 million, respectively, from customers located outside of the U.S.

Net Loss Per Share

Basic net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and unvested restricted stock and restricted stock contingently issuable upon achievement of certain market conditions are considered to be common stock equivalents, but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share applicable to common stockholders was the same for all periods presented.

Guarantees

As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company’s request in such capacity. The term of the indemnification is the officer’s or director’s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid.

The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company’s leases.

In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company’s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements.

As of September 30, 2019 and December 31, 2018, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.

Leases

The Company adopted Topic 842, Leases (“ASC 842”), using the modified retrospective approach through a cumulative-effect adjustment and utilizing the effective date of January 1, 2019 as its date of initial application, with prior periods unchanged and presented in accordance with the previous guidance in Topic 840, Leases (“ASC 840”).

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued lease payments. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.

In accordance with the guidance in ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.) Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.

The Company made the policy election to not separate lease and non-lease components. Each lease component and the related non-lease components are accounted for together as a single component.

Revenue Recognition

The Company generates revenue from the sale of instruments, consumable diagnostic tests, related services, reagent rental agreements and research and development agreements with third parties. Pursuant to ASC 606, Revenue from Contracts with Customers (“ASC 606”), revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration the Company expects to be entitled to receive in exchange for these goods and services.

Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon shipment, or over time, as services are performed.


Most of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. Excluded from the transaction price are sales tax and other similar taxes which are presented on a net basis.

Product revenue is generated by the sale of instruments and consumable diagnostic tests predominantly through the Company’s direct sales force in the United States and distributors in geographic regions outside the United States. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors’ receipt of payment from their end-user customers. The Company either sells instruments to customers and international distributors, or retains title and places the instrument at the customer site pursuant to a reagent rental agreement. When an instrument is purchased by a customer, the Company recognizes revenue when the related performance obligation is satisfied (i.e. when the control of an instrument has passed to the customer; typically, at shipping point). When the instrument is placed under a reagent rental agreement, the Company’s customers generally agree to fixed term agreements, which can be extended, and incremental charges on each consumable diagnostic test purchased. Revenue from the sale of consumable diagnostic tests (under a reagent rental agreement) is recognized upon shipment. The transaction price from consumables purchases is allocated between the lease of the instrument (under a contingent rent methodology as provided for in ASC 842, Leases), and the consumables when related performance obligations are satisfied, as a component of lease and product revenue, and is included as Instrument Rentals in the below table. Revenue associated with reagent rental consumables purchases is currently classified as variable consideration and constrained until a purchase order is received and related performance obligations have been satisfied. Shipping and handling costs billed to customers in connection with a product sale are recorded as a component of the transaction price and allocated to product revenue in the condensed consolidated statements of operations and comprehensive loss as they are incurred by the Company in fulfilling its performance obligations.

Direct sales of instruments include warranty, maintenance and technical support services typically for one year following the installation of the purchased instrument (“Maintenance Services”). Maintenance Services are separate performance obligations as they are service based warranties and are recognized on a straight-line basis over the service delivery period. After the completion of the initial Maintenance Services period, customers have the option to renew or extend the Maintenance Services typically for additional one-year periods in exchange for additional consideration. The extended Maintenance Services are also service based warranties that represent separate purchasing decisions. The Company recognizes revenue allocated to the extended Maintenance Services performance obligation on a straight-line basis over the service delivery period.

Fees paid to member-owned group purchasing organizations (“GPOs”) are deducted from related product revenues.

The Company warrants that consumable diagnostic tests will be free from defects, when handled according to product specifications, for the stated life of the product. To fulfill valid warranty claims, the Company provides replacement product free of charge. Accordingly, the Company accrues warranty expense associated with the estimated defect rates of the consumable diagnostic tests.

Revenue earned from activities performed pursuant to research and development agreements is reported as research revenue in the condensed consolidated statements of operations and comprehensive loss, and is recognized over time using an input method as the work is completed. The related costs are expensed as incurred as research and development expense. The timing of receipt of cash from the Company’s research and development agreements generally differs from when revenue is recognized. Milestones are contingent on the occurrence of future events and are considered variable consideration being constrained until the Company believes a significant revenue reversal will not occur. Refer to Note 11 for further details regarding the Company’s research and development arrangements.

Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contribution revenue is recognized when all donor-imposed conditions have been met.

Disaggregation of Revenue

The Company disaggregates revenue from contracts with customers by type of products and services, as it best depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The following table disaggregates our revenue by major source (in thousands):

	Three months ended, September 30,				Nine months ended, September 30,
	2019		2018		2019		2018
Product Revenue
Instruments	$	543	$	504	$	1,540	$	1,213
Consumables		604		608		2,054		1,929
Instrument rentals		30		106		171		344
Total Product Revenue		1,177		1,218		3,765		3,486
Research Revenue		56		1,248		269		5,222
Contribution Revenue		444		—		1,232		—
Total Revenue	$	1,677	$	2,466	$	5,266	$	8,708

Remaining Performance Obligations

Remaining performance obligations represent the transaction price of firm orders for which work has not been performed or goods and services have not been delivered. As of September 30, 2019, the aggregate amount of transaction price allocated to remaining performance obligations for contracts with an original duration greater than one year was $3.5 million, of which $3.0 million is constrained revenue. We do not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed. The Company expects to recognize revenue on the remaining performance obligations over the next two years.

Significant Judgments

Our contracts with customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment. Once we determine the performance obligations, the Company determines the transaction price, which includes estimating the amount of variable consideration, based on the most likely amount, to be included in the transaction price, if any. We then allocate the transaction price to each performance obligation in the contract based on a relative stand-alone selling price method. The corresponding revenue is recognized as the related performance obligations are satisfied as discussed in the revenue categories above.

Judgment is required to determine the standalone selling price for each distinct performance obligation. We determine standalone selling price based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, we estimate the standalone selling price taking into account available information such as market conditions and the expected costs and margin related to the performance obligations.

Contract Assets and Liabilities

The Company did not record any contract assets at September 30, 2019 and December 31, 2018.

The Company’s contract liabilities consist of upfront payments for research and development contracts and Maintenance Services on instrument sales. We classify these contract liabilities in deferred revenue as current or noncurrent based on the timing of when we expect to recognize revenue. Contract liabilities were $0.6 million at September 30, 2019 and $0.6 million at December 31, 2018. Revenue recognized in the three and nine months ended September 30, 2019 relating to contract liabilities at December 31, 2018 was $0.1 million and $0.4 million, respectively, and related to performance of research and development services and straight-line revenue recognition associated with maintenance agreements.

Cost to Obtain and Fulfill a Contract

The Company does not meet the recoverability criteria to capitalize costs to obtain or fulfill instrument purchases. Reagent rental agreements do not meet the recoverability criteria to capitalize costs to obtain the contracts and the costs to fulfill the contracts are under the scope of ASC 842. At the end of each reporting period, the Company assesses whether any circumstances have changed to meet the criteria for capitalization. The Company did not incur any expenses to obtain research and development agreements and costs to fulfill those contracts do not generate or enhance resources of the entity. As such, no costs to obtain or fulfill contracts have been capitalized at period end.

Cost of Product Revenue

Cost of product revenue includes the cost of materials, direct labor and manufacturing overhead costs used in the manufacture of consumable diagnostic tests sold to customers and related license and royalty fees. Cost of product revenue also includes depreciation on revenue generating T2Dx instruments that have been placed with customers under reagent rental agreements; costs of materials, direct labor and manufacturing overhead costs on the T2Dx instruments sold to customers; and other costs such as customer support costs, royalties and license fees, warranty and repair and maintenance expense on the T2Dx instruments that have been placed with customers under reagent rental agreements.

Research and Development Costs

Costs incurred in the research and development of the Company’s product candidates are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including activities associated with performing services under research revenue arrangements and contribution agreements, costs associated with the manufacture of developed products and include salaries and benefits, stock compensation, research‑related facility and overhead costs, laboratory supplies, equipment and contract services.

Recent Accounting Standards

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

Accounting Standards Adopted

In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”) in order to increase transparency and comparability among organizations by recognizing right-of-use assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-02 requires a lessee to recognize a lease liability for its future lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet for most lease arrangements. The new standard also changes many key definitions, including the definition of a lease. The new standard includes a short-term lease exception for leases with a term of 12 months or less, as part of which a lessee can make an accounting policy election not to recognize right-of-use assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases using classification criteria that are substantially similar to the previous guidance in ASC 840.

ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 (including interim periods within those periods) and early adoption is permitted. In August 2018, the FASB issued ASU 2018-11, Leases, Targeted Improvements, which provides a new transition option in which an entity initially applies ASU 2016-02 at the adoption date and recognizes a cumulative-effect adjustment in the period of adoption. Prior period comparative balances will not be adjusted. The Company used the new transition option and was also utilizing the package of practical expedients that allows it to not reassess: (1) whether any expired or existing contracts are or contain leases, (2) lease classification for any expired or existing leases, and (3) initial direct costs for any existing leases. We also used the short-term lease exception for leases with a term of twelve months or less. Additionally, the Company used the practical expedient that allowed each separate lease component of a contract and its associated non-lease components to be treated as a single lease component. As of the January 1, 2019 effective date the Company identified eight operating lease arrangements and two finance lease arrangements in which it is a lessee. The adoption of this standard resulted in the recognition of operating lease liabilities and right-of-use assets of $5.6 million and $4.8 million, respectively, on the Company’s balance sheet, with the difference relating to a reclassification of the current accrued rent liability of $0.8 million as a reduction to the right-of-use-assets for its operating leases.

In calculating the present value of the lease payments, the Company applied an individual discount rate for each of its leases, and determined the appropriate discount rate based on the remaining lease terms at the date of adoption. As the lessee to several lease agreements, the Company did not have insight into the relevant information that would be required to arrive at the rate implicit in the lease. Therefore, the Company utilized its outstanding borrowings as a benchmark to determine its incremental borrowing rate for its leases. The benchmark rate was adjusted to arrive at an appropriate discount rate for each lease.

Under the new guidance, lessor accounting is largely unchanged. As of September 30, 2019, the Company was the lessor of T2Dx instruments. The lease agreements typically do not include fixed rental payments, but rather rental revenue is earned through usage-based variable lease payments. In accordance with ASC 842 the Company recognized lease revenue related to variable lease payments in the period in which it was earned. For the three and nine months ended September 30, 2019, the Company recognized $0.1 million and $0.2 million, respectively, of lease revenue for instrument rentals.

In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”), which expands the scope of Compensation – Stock Compensation (“Topic 718”) to include share-based payment transactions for acquiring goods and services from nonemployees. This amendment applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The Company adopted ASU 2018-07 on January 1, 2019. The impact was immaterial to the financial statements.

In June 2018, the FASB issued ASU No. 2018-08, Not-For-Profit Entities – Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made (“ASU 2018-08”). ASU 2018-18 clarifies how an entity determines whether a resource provider is participating in an exchange transaction by evaluating whether the resource provider is receiving commensurate value in return for the resources transferred. The guidance is effective for annual periods beginning after June 15, 2018, including interim periods within those annual periods, and has been adopted on a modified prospective basis. The modified prospective adoption is applied to agreements that are not completed as of the effective date, or entered into after the effective date. Under the modified prospective adoption approach, prior period results have not been restated and no cumulative-effect adjustment has been recorded. As a result of applying ASU 2018-18, the Company recorded revenue of $0.1 million and $0.9 million earned under its agreement with CARB-X (Note 11) as contribution revenue during the three and nine months ended September 30, 2019, respectively.

Accounting Standards Issued, Not Adopted

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (“ASU 2018-13”), which eliminates, adds and modifies certain disclosure requirements for fair value measurements. The amendment is effective for interim and annual reporting periods beginning after December 15, 2019. The Company is currently assessing the impact this will have on the financial statements.

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (“ASU 2018-18”), which clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers. Certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, ASU 2018-18 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. ASU 2018-18 should be applied retrospectively to the date of initial application of ASC 606. This guidance is effective for interim and fiscal periods beginning after December 15, 2019. The Company is currently assessing the impact this will have on the financial statements.

Emerging Growth Company Status

In April 2012, the Jumpstart Our Business Startups Act, or the JOBS Act, was enacted in the United States. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, as amended, for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As of December 31, 2019, the Company will no longer qualify as an emerging growth company.

Fair Value Measurements

9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

3. Fair Value Measurements

The Company measures the following financial assets at fair value on a recurring basis. There were no transfers between levels of the fair value hierarchy during any of the periods presented. The following tables set forth the Company’s financial assets carried at fair value categorized using the lowest level of input applicable to each financial instrument as of September 30, 2019 and December 31, 2018 (in thousands):

	Balance at September 30, 2019		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash	$	11,926	$	11,926	$	—	$	—
Money market funds		4,287		4,287		—		—
Restricted cash		180		180		—		—
	$	16,393	$	16,393	$	—	$	—


Liabilities:
Derivative liability	$	2,603	$	—	$	—	$	2,603
	$	2,603	$	—	$	—	$	2,603

	Balance at December 31, 2018		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash	$	6,868	$	6,868	$	—	$	—
Money market funds		43,937		43,937		—		—
Restricted cash		180		180		—		—
	$	50,985	$	50,985	$	—	$	—


Liabilities:
Derivative liability	$	2,142	$	—	$	—	$	2,142
	$	2,142	$	—	$	—	$	2,142

The Company maintains certificates of deposit, classified as restricted cash, for $0.2 million (Note 4). The Company’s Term Loan Agreement with CRG (Note 6) contains certain provisions that change the underlying cash flows of the instrument, including acceleration of the obligations under the Term Loan Agreement under an event of default. In addition, under certain circumstances, a default interest rate of an additional 4.0% per annum will apply at the election of CRG on all outstanding obligations during the occurrence and continuance of an event of default. The Company concluded that these features are not clearly and closely related to the host instrument, and represent a single compound derivative that is required to be re-measured at fair value on a quarterly basis.

In March 2019, the Term Loan Agreement was amended to reduce the 2019 minimum revenue target to $9.0 million and eliminate the 2018 revenue target. In September 2019, the Term Loan Agreement was amended to extend the interest-only payment period through December 31, 2021, to extend the initial principal repayment to March 31, 2022, and to reduce the minimum revenue targets. The fair value of the derivative at September 30, 2019 and December 31, 2018 is $2.6 million and $2.1 million, respectively. The estimated fair value of the derivative, at both dates, was determined using a probability-weighted discounted cash flow model that includes contingent interest payments under the following scenarios: 4% contingent interest beginning in 2020 (70%) and 4% contingent interest beginning in 2021 (30%). Should the Company’s assessment of these probabilities change, including amendments of certain revenue targets, there could be a change to the fair value of the derivative liability.

The following table provides a roll-forward of the fair value of the derivative liability (in thousands):

Balance at December 31, 2018	$	2,142
Change in fair value of derivative liability, recorded as interest expense		461
Balance at September 30, 2019	$	2,603

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Supplemental Balance Sheet Information

9 Months Ended

Sep. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Supplemental Balance Sheet Information

5. Supplemental Balance Sheet Information

Accounts Receivable

Accounts receivable consists of the following (in thousands):

	September 30, 2019		December 31, 2018
Accounts receivable	$	873	$	1,786
Unbilled receivables		700		—
Total accounts receivable	$	1,573	$	1,786

Inventories

Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis and are comprised of the following (in thousands):

	September 30, 2019		December 31, 2018
Raw materials	$	1,903	$	639
Work-in-process		1,586		1,713
Finished goods		621		325
Total inventories, net	$	4,110	$	2,677

Property and Equipment

Property and equipment consists of the following (in thousands):

	September 30, 2019			December 31, 2018
Office and computer equipment	$	409		$	409
Software		762			751
Laboratory equipment		4,747			4,636
Furniture		194			200
Manufacturing equipment		672			695
Manufacturing tooling and molds		255			255
T2-owned instruments and components		6,879			6,796
Leasehold improvements		3,497			3,437
Construction in progress		1,698			1,443
		19,113			18,622
Less accumulated depreciation and amortization		(12,799	)		(11,307	)
Property and equipment, net	$	6,314		$	7,315

Construction in progress is primarily comprised of equipment that have not been placed in service. T2-owned instruments and components is comprised of raw materials and work-in-process inventory that are expected to be used or used to produce T2-owned instruments, based on our business model and forecast, and completed instruments that will be used for internal research and development, clinical studies or reagent rental agreements with customers. At September 30, 2019, there were $0.6 million of raw materials and work-in-process inventory in T2-owned instruments and components compared to $0.3 million at December 31, 2018. Completed T2-owned instruments are placed in service once installation procedures are completed and are depreciated over five years. Depreciation expense for T2-owned instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of product revenue and totaled approximately $0.2 million for the three months ended September 30, 2019 and 2018 and $0.6 million and $0.7 million for the nine months ended September 30, 2019 and 2018, respectively. Depreciation expense for T2-owned instruments used for internal research and development and clinical studies is recorded as a component of research and development expense. Depreciation and amortization expense of $0.5 million and $0.6 million was charged to operations for the three months ended September 30, 2019 and 2018, respectively, and $1.7 million and $1.9 million for the nine months ended September 30, 2019 and 2018, respectively.

There were no property and equipment under finance leases included with property and equipment as of September 30, 2019. Total property and equipment, gross, included $3.6 million for property and equipment recorded under finance leases as of December 31, 2018. Accumulated depreciation and amortization included $2.6 million for property and equipment recorded under finance leases as of December 31, 2018

Accrued Expenses

Accrued expenses consist of the following (in thousands):

	September 30, 2019		December 31, 2018
Accrued payroll and compensation	$	2,809	$	2,940
Accrued research and development expenses		297		359
Accrued professional services		291		576
Operating lease liabilities		1,913		—
Other accrued expenses		3,490		2,198
Total accrued expenses and other current liabilities	$	8,800	$	6,073

At September 30, 2019 and December 31, 2018, the Company classified $2.1 million and $1.4 million, respectively, related to a fee associated with the Company’s Term Loan Agreement (Note 6), as other accrued expenses in the table above to match the current classification of the associated debt.

Notes Payable

9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Notes Payable

6. Notes Payable

Future principal payments on the notes payable are as follows (in thousands):

	September 30, 2019			December 31, 2018
Term loan agreement, net of deferred issuance costs of $2.0 million and $1.8 million, respectively	$	42,258		$	41,419
Equipment lease credit facility, net of immaterial deferred issuance costs		—			954
Total notes payable		42,258			42,373
Less: current portion of notes payable		(42,258	)		(42,373	)
Notes payable, net of current portion	$	—		$	—

The Term Loan Agreement with CRG is classified as a current liability on the balance sheet at September 30, 2019 and December 31, 2018 based on the Company’s consideration of the probability of violating the minimum liquidity covenant included in the Term Loan Agreement. The Term Loan Agreement includes a subjective acceleration clause whereby an event of default, including a material adverse change in the business, operations, or conditions (financial or otherwise), could result in the acceleration of the obligations under the Term Loan Agreement. The contractual terms of the agreement, as amended, require quarterly principal payments of $12.0 million commencing March 31, 2022 through maturity December 31, 2022, respectively.

Term Loan Agreement

In December 2016, the Company entered into a Term Loan Agreement (the “Term Loan Agreement”) with CRG. The Company initially borrowed $40.0 million pursuant to the Term Loan Agreement, which has a six-year term with four years of interest-only payments (through December 30, 2020), after which quarterly principal and interest payments will be due through the December 30, 2022 maturity date. Interest on the amounts borrowed under the Term Loan Agreement accrues at an annual fixed rate of 11.5%, 3.5% of which may be deferred during the interest-only period by adding such amount to the aggregate principal loan amount. In addition, if the Company achieves certain financial performance metrics, the loan will convert to interest-only until the December 30, 2022 maturity, at which time all unpaid principal and accrued unpaid interest will be due and payable. The Company is required to pay CRG a financing fee based on the loan principal amount drawn. The Company is also required to pay a final payment fee of 8.0% of the principal outstanding upon repayment. The Company is accruing the final payment fee as interest expense and it is included as a current liability at September 30, 2019 and December 31, 2018 on the balance sheet.

The Company may prepay all or a portion of the outstanding principal and accrued unpaid interest under the Term Loan Agreement at any time upon prior notice subject to a certain prepayment fee during the first five years of the term and no prepayment fee thereafter. As security for its obligations under the Term Loan Agreement the Company entered into a security agreement with CRG whereby the Company granted a lien on substantially all of its assets, including intellectual property. The Term Loan Agreement also contains customary affirmative and negative covenants for a credit facility of this size and type, including a requirement to maintain a minimum cash balance. The Term Loan Agreement also requires the Company to achieve certain revenue targets, whereby the Company is required to pay double the amount of any shortfall as an acceleration of principal payments. In March 2019, the Term Loan Agreement was amended to reduce the 2019 minimum revenue target to $9.0 million and eliminate the 2018 revenue covenant. In exchange for the amendment, the Company agreed to reset the strike price of the warrants to purchase a total of 528,958 shares of the Company’s common stock, issued in connection with the Term Loan Agreement, from $8.06 per share to $4.35 per share (Note 9).

In September 2019, the Term Loan Agreement was amended to extend the interest-only payment period through December 31, 2021, to extend the initial principal repayment to March 31, 2022, and to reduce the minimum product revenue target for 2019 from $9 million to $4 million, for the twenty-four month period beginning on January 1, 2019 from $95 million to $15 million and for the twenty-four month period beginning on January 1, 2020 from $140 million to $43 million. The final payment fee was increased from 8% to 10% of the principal amount outstanding upon repayment. The Company issued to CRG warrants to purchase 568,291 shares of the Company’s common stock (“New Warrants”) (Note 9) at an exercise price of $1.55, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company. The Company also reduced the exercise price for the warrants previously issued to CRG to purchase an aggregate of 528,958 shares of the Company’s common stock to $1.55. All of the New Warrants are exercisable any time prior to September 9, 2029, and all of the previously issued warrants are exercisable any time prior to December 30, 2026. The Company accounted for the March 2019 and September 2019 amendments as modifications to the Term Loan Agreement.

The Term Loan Agreement includes a subjective acceleration clause whereby an event of default, including a material adverse change in the business, operations, or conditions (financial or otherwise), could result in the acceleration of the obligations under the Term Loan Agreement. Under certain circumstances, a default interest rate of an additional 4.0% per annum will apply at the election of CRG on all outstanding obligations during the occurrence and continuance of an event of default. CRG has not exercised its right under this clause, as there have been no such events. The Company believes the likelihood of CRG exercising this right is remote.

The Company assessed the terms and features of the Term Loan Agreement, including the interest-only period and the acceleration of the obligations under the Term Loan Agreement under an event of default, in order to identify any potential embedded features that would require bifurcation. In addition, under certain circumstances, a default interest rate of an additional 4.0% per annum will apply at the election of CRG on all outstanding obligations during the occurrence and continuance of an event of default, The Company concluded that the features of the Term Loan Agreement are not clearly and closely related to the host instrument, and represent a single compound derivative that is required to be re-measured at fair value on a quarterly basis.

The fair value of the derivative at September 30, 2019 and December 31, 2018 is $2.6 million and $2.1 million, respectively. The Company classified the derivative liability as accrued expenses and other current liabilities on the balance sheet at September 30, 2019 and December 31, 2018 to match the classification of the related Term Loan Agreement.

Equipment Lease Credit Facility

In October 2015, the Company signed a $10.0 million Credit Facility (the “Credit Facility”) with Essex Capital Corporation (the “Lessor”) to fund capital equipment needs. As one of the conditions of the Term Loan Agreement, the Credit Facility is capped at a maximum of $5.0 million. Under the Credit Facility, Essex will fund capital equipment purchases presented by the Company. The Company will repay the amounts borrowed in 36 equal monthly installments from the date of the amount funded. At the end of the 36 month lease term, the Company has the option to (a) repurchase the leased equipment at the lesser of fair market value or 10% of the original equipment value, (b) extend the applicable lease for a specified period of time, which will not be less than one year, or (c) return the leased equipment to the Lessor.

In April 2016 and June 2016, the Company completed the first two draws under the Credit Facility, of $2.1 million and $2.5 million, respectively. The Company made monthly payments of $67,000 under the first draw and $79,000 under the second draw. The borrowings under the Credit Facility were treated as finance leases and are included in property and equipment on the balance sheet. The amortization of the assets conveyed under the Credit Facility is included as a component of depreciation expense. During the three months ended September 30, 2019, the Company repurchased the equipment for $0.3 million in accordance with the terms of the Credit Facility.

Stockholders' Equity

9 Months Ended

Sep. 30, 2019

Equity [Abstract]

Stockholders' Equity

7. Stockholders’ Equity

Equity Distribution Agreement

On July 30, 2019, the Company entered into the Sales Agreement with Canaccord, as agent, pursuant to which the Company may offer and sell shares of common stock, for aggregate gross sale proceeds of up to $30.0 million from time to time through Canaccord.

Upon delivery of a placement notice based on the Company’s instructions and subject to the terms and conditions of the Sales Agreement, Canaccord may sell the shares by methods deemed to be an “at the market” offering, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company. The Company is not obligated to make any sales of shares under the Sales Agreement. The Company or Canaccord may suspend or terminate the offering of shares upon notice to the other party, subject to certain conditions. Canaccord will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of Nasdaq.

The Company has agreed to pay Canaccord for its services of acting as agent 3% of the gross proceeds from the sale of the shares pursuant to the Sales Agreement. The Company has also agreed to provide Canaccord with customary indemnification for certain liabilities. At September 30, 2019, legal and accounting fees associated with the Sales Agreement were immaterial. Legal and accounting fees are expected to be changed to share capital upon issuance of shares under the Sales Agreement.

During the three months ended September 30, 2019, the Company sold 1,679,387 shares for net proceeds of $1.9 million after expenses in connection with the Sales Agreement.

Purchase Agreement

On July 29, 2019, the Company entered into a $30.0 million Purchase Agreement with Lincoln Park, pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $30.0 million in value of its shares of common stock from time to time over a 36-month period starting from the effective date of the respective registration statement.

The Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase. The amount of a purchase may be increased under certain circumstances provided, however, that Lincoln Park’s committed obligation under any single purchase shall not exceed $2.0 million. The purchase price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the Purchase Agreement.

In consideration for the execution and delivery of the Purchase Agreement, the Company issued 413,349 shares of common stock to Lincoln Park.

Public Offering

On June 4, 2018, the Company sold 7,015,000 shares of its common stock in a public offering at $7.50 per share, for an aggregate gross cash purchase price of $52.6 million, resulting in net proceeds of $49.2 million after underwriters discount and expenses.

Stock-Based Compensation

9 Months Ended

Sep. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

8. Stock-Based Compensation

Stock Incentive Plans

2006 Stock Incentive Plan

The Company’s 2006 Stock Option Plan (“2006 Plan”) was established for granting stock incentive awards to directors, officers, employees and consultants of the Company. Upon closing of the Company’s IPO in August 2014, the Company ceased granting stock incentive awards under the 2006 Plan. The 2006 Plan provided for the grant of incentive and non-qualified stock options and restricted stock grants as determined by the Company’s board of directors. Under the 2006 Plan, stock options were generally granted with exercise prices equal to or greater than the fair value of the common stock as determined by the board of directors, expired no later than 10 years from the date of grant, and vest over various periods not exceeding 4 years.

2014 Stock Incentive Plan

The Company’s 2014 Incentive Award Plan (“2014 Plan”, and together with the 2006 Plan, the “Stock Incentive Plans”), provides for the issuance of shares of common stock in the form of stock options, awards of restricted stock, awards of restricted stock units, performance awards, dividend equivalent awards, stock payment awards and stock appreciation rights to directors, officers, employees and consultants of the Company. Since the establishment of the 2014 Plan, the Company has primarily granted stock options and restricted stock units. Generally, stock options are granted with exercise prices equal to or greater than the fair value of the common stock on the date of grant, expire no later than 10 years from the date of grant, and vest over various periods not exceeding 4 years.

The number of shares reserved for future issuance under the 2014 Plan is the sum of (1) 823,529 shares, (2) any shares that were granted under the 2006 Plan which are forfeited, lapsed unexercised or are settled in cash subsequent to the effective date of the 2014 Plan and (3) an annual increase on the first day of each calendar year beginning January 1, 2015 and ending on January 1, 2024, equal to the lesser of (A) 4% of the shares outstanding (on an as-converted basis) on the final day of the immediately preceding calendar year, and (B) such smaller number of shares determined by the Company’s Board of Directors. As of September 30, 2019, there were 407,870 shares available for future grant under the Stock Incentive Plans.

Inducement Award Plan

The Company’s Amended and Restated Inducement Award Plan (“Inducement Plan”), which was adopted in March 2018 and amended and restated in February 2019, provides for the granting of equity awards to new employees, which includes options, restricted stock awards, restricted stock units, performance awards, dividend equivalent awards, stock payment awards and stock appreciation rights. The aggregate number of shares of common stock which may be issued or transferred pursuant to awards under the Inducement Plan is 1,625,000 shares. Any awards that forfeit, expire, lapse, or are settled for cash without the delivery of shares to the holder are available for the grant of an award under the Inducement Plan. Any shares repurchased by or surrendered to the Company that are returned shall be available for grant of an award under the Inducement Plan. The payment of dividend equivalents in cash in conjunction with any outstanding award shall not be counted against the shares available for issuance under the Inducement Plan. As of September 30, 2019, there were 752,708 shares available for future grant under the Inducement Plan.

Stock Options

During the nine months ended September 30, 2019 and 2018, the Company granted stock options with an aggregate fair value of $3.8 million and $5.5 million, respectively, which are being amortized into compensation expense over the vesting period of the options as the services are being provided.

The following is a summary of option activity under the Stock Incentive Plans and Inducement Plan (in thousands, except share and per share amounts):

	Number of Shares			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (In years)		Aggregate Intrinsic Value
Outstanding at December 31, 2018		4,241,833		$	6.98		7.02	$	471
Granted		2,683,200			2.11
Exercised		(938	)		2.68
Forfeited		(373,388	)		5.28
Cancelled		(119,270	)		7.81
Outstanding at September 30, 2019		6,431,437		$	5.03		7.46	$	2,148
Exercisable at September 30, 2019		2,996,830		$	7.30		5.35	$	257
Vested or expected to vest at September 30, 2019		5,740,731		$	5.28		7.23	$	1,791

The weighted-average grant date fair values of stock options granted in the nine month periods ended September 30, 2019 and 2018 were $1.40 per share and $3.55 per share, respectively, and were calculated using the following estimated assumptions:

	Nine Months Ended
	September 30,
	2019			2018
Weighted-average risk-free interest rate		1.98	%		2.66	%
Expected dividend yield		—	%		—	%
Expected volatility		78	%		68	%
Expected terms	6.0 years			6.0 years

The total fair values of options that vested during the nine months ended September 30, 2019 and 2018 were $2.4 million and $2.3 million, respectively.

As of September 30, 2019, there was $6.5 million of total unrecognized compensation cost related to non-vested stock options granted under the Stock Incentive Plans and Inducement Plan. Total unrecognized compensation cost will be adjusted for future changes in the estimated forfeiture rate. The Company expects to recognize that cost over a remaining weighted-average period of 2.7 years as of September 30, 2019.

Restricted Stock Units

During the nine months ended September 30, 2019, the Company awarded shares of restricted stock units to certain employees and directors at no cost to them, which cannot be sold, assigned, transferred or pledged during the restriction period. The restricted stock and restricted stock units, excluding any restricted stock units with market conditions, vest through the passage of time, assuming continued employment. Restricted stock units are not included in issued and outstanding common stock until the shares are vested and released. As of December 31, 2018, 78,172 restricted stock units had vested but were not reflected as outstanding shares due to a deferred release date. These restricted stock units are reflected as outstanding shares at September 30, 2019. During the year ended December 31, 2018, an additional 73,172 restricted stock units vested but are not reflected as outstanding shares at September 30, 2019 and December 31, 2018 due to a deferred release date. The fair value of the restricted stock units, at the time of the grant, is expensed on a straight line basis. The granted restricted stock units had an aggregate fair value of $1.9 million, which are being amortized into compensation expense over the vesting period of the restricted stock units as the services are being provided.

Included in the nonvested restricted stock units at September 30, 2019 are 755,168 restricted stock units with market conditions, which vest upon the achievement of stock price targets. The compensation cost for restricted stock units with market conditions is being recorded over the derived service period and was $0.2 million and $0.9 million for the three months ended September 30, 2019 and 2018, respectively, and $1.0 million and $3.6 million for the nine months ended September 30, 2019 and 2018, respectively.

The following is a summary of restricted stock unit activity under the 2014 Plan (in thousands, except share and per share amounts):

	Number of Shares			Weighted-Average Grant Date Fair Value
Nonvested at December 31, 2018		1,198,634			5.04
Granted		589,142			3.23
Vested		(189,129	)		6.41
Forfeited		(286,889	)		4.41
Cancelled		—			—
Nonvested at September 30, 2019		1,311,758			4.17

As of September 30, 2019, there was $1.6 million of total unrecognized compensation cost related to nonvested restricted stock units granted under the 2014 Plan. Total unrecognized compensation cost will be adjusted for future changes in the estimated forfeiture rate. The Company expects to recognize that cost over a remaining weighted-average period of 2.13 years, as of September 30, 2019.

Stock-Based Compensation Expense

The following table summarizes the stock-based compensation expense resulting from awards granted under Stock Incentive Plans, including the Inducement Plan and 2014 ESPP, that was recorded in the Company’s results of operations for the periods presented (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Cost of product revenue	$	7	$	23	$	295	$	408
Research and development		283		409		975		1,271
Selling, general and administrative		862		1,601		3,216		5,561
Total stock-based compensation expense	$	1,152	$	2,033	$	4,486	$	7,240

For the three months ended September 30, 2019 and 2018, stock-based compensation expenses capitalized as part of inventory or T2Dx instruments and components, respectively, were immaterial. For the nine months ended September 30, 2019, stock-based compensation expenses capitalized as part of inventory or T2Dx instruments and components, respectively, were immaterial. For the nine months ended September 30, 2018 $0.3 million of stock-based compensation expenses were capitalized as part of inventory or T2 instruments and components, respectively.

Net Loss Per Share

9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

Net Loss Per Share

10. Net Loss Per Share

The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented:

	Three and Nine Months Ended September 30,
	2019		2018
Options to purchase common shares		6,431,437		4,236,595
Restricted stock units		1,311,758		1,202,123
Warrants to purchase common stock		1,097,249		528,958
Total		8,840,444		5,967,676

Co-Development Agreements

9 Months Ended

Sep. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Co-Development Agreements

11. Co-Development Agreements

Canon US Life Sciences

On February 3, 2015, the Company entered into a Co-Development Partnership Agreement (the “Co-Development Agreement”) with Canon U.S. Life Sciences, Inc. (“Canon”) to develop a diagnostic test panel to rapidly detect Lyme disease. On September 21, 2016, Canon became a related party when the Company sold the Canon shares for an aggregate cash purchase price of $39.7 million, which represented 19.9% of the outstanding shares of common stock of the Company.

Under the Co-Development Agreement, the Company recorded revenue of $0.1 million and $0.2 million for the three months ended September 30, 2019 and 2018, respectively. The Company recorded revenue of $0.2 million and $1.5 million during the nine months ended September 30, 2019 and 2018, respectively. The Company expects to record revenue over the next four months.

Allergan Sales, LLC

On November 1, 2016, the Company entered into a Co-Development, Collaboration and Co-Marketing Agreement (the “Allergan Agreement”) with Allergan Sales, LLC (“Allergan Sales”) to develop (1) a direct detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate (the “T2Bacteria II Panel”), and (2) a direct detection diagnostic test panel for testing drug resistance directly in whole blood (the “T2GNR Panel” and, together with the T2Bacteria II Panel, the “Developed Products”). In addition, both the Company and Allergan Sales will participate in a joint research and development committee and Allergan Sales will receive the right to cooperatively market T2Candida, T2Bacteria, and the Developed Products under the Allergan Agreement to certain agreed-upon customers. The Company achieved the final developmental milestone under the Allergan Agreement in October 2018.

The Company did not record any revenue for the three and nine months ended September 30, 2019 and recorded revenue of $0.7 million and $2.9 million for the three and nine months ended September 30, 2018, respectively, under the Allergan Agreement.

CARB-X

In March 2018, the Company was awarded a grant of up to $2.0 million from CARB-X. The collaboration with CARB-X will be used to accelerate the development of new tests to identify bacterial pathogens and resistance markers directly in whole blood more rapidly than is possible using today’s diagnostic tools. The new tests aim to expand the T2Dx instrument product line by detecting 20 additional bacterial species and resistance targets, with a focus on blood borne pathogens on the United States Centers for Disease Control and Prevention (“CDC”) antibiotic resistance threat list.

Under this cost-sharing agreement, the Company may be reimbursed up to $1.1 million, with the possibility of up to an additional $0.9 million based on the achievement of certain project milestones. In January 2019, the Company was awarded the $0.9 million reimbursement option.

The Company recorded revenue of $0.1 million and $0.4 million for the three months ended September 30, 2019 and 2018, respectively, under the CARB-X Agreement. The Company recorded revenue of $0.9 million and $0.9 million for the nine months ended September 30, 2019 and 2018, respectively, under the CARB-X agreement. The Company recorded CARB-X revenue as contribution revenue in 2019 upon adoption of a new accounting standard and research revenue in 2018. As the Company has recognized the $0.9 million that was awarded under the reimbursement option, the Company will not recognize any additional revenue under the CARB-X agreement.

US Government Contract

In September 2019, the Biomedical Advanced Research and Development Authority (“BARDA”) awarded the Company a milestone-based contract, with an initial value of $6 million, and a potential value of up to $69 million, if BARDA awards all contract options. BARDA operates within the Office of the Assistant Secretary for Preparedness and Response (“ASPR”) at the U.S. Department of Health and Human Services’ (“HHS”). If BARDA awards and the Company completes all options, the Company’s management believes it will enable a significant expansion of the Company’s current portfolio of diagnostics for sepsis-causing pathogen and anti-biotic resistance genes.

The Company recorded revenue of $0.3 million for the three and nine months ended September 30, 2019.

Leases

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Leases

12. Leases

Operating Leases

The Company leases certain office space, laboratory space, and equipment. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. The Company does not recognize right-of-use assets or lease liabilities for leases determined to have a term of 12 months or less. For new and amended leases beginning in 2019 and after, the Company has elected to account for the lease and non-lease components as a combined lease component.

In August 2010, the Company entered into an operating lease for office and laboratory space at its headquarters in Lexington, Massachusetts. The lease commenced in January 2011, with the Company providing a security deposit of $400,000. In accordance with the operating lease agreement, the Company reduced its security deposit to $180,000 in January 2018, which is recorded as restricted cash in the condensed consolidated balance sheets. In March 2017, the Company entered into an amendment to extend the term to December 2021.

In May 2013, the Company entered into an operating lease for additional office, laboratory and manufacturing space in Wilmington, Massachusetts. In August 2018, the Company entered into an amendment to extend the term to December 2020.

In November 2014, the Company entered into an agreement to rent additional office space in Lexington, Massachusetts. In April 2015, the Company entered into an amendment to extend the term to December 31, 2017. In connection with this agreement, the Company paid a security deposit of $50,000, which is recorded as a component of other assets in the condensed consolidated balance sheets. In May 2015, the Company entered into an amendment to expand existing manufacturing facilities in Lexington, Massachusetts. In September 2017, the Company entered into an amendment to extend the term to December 31, 2021.

In November 2014, the Company entered into a lease for additional laboratory space in Lexington, Massachusetts. The lease term commenced in April 2015 and extended for six years. The rent expense, inclusive of the escalating rent payments, is recognized on a straight-line basis over the lease term. As an incentive to enter into the lease, the landlord paid approximately $1.4 million of the $2.2 million space build-out costs. Prior to the adoption of ASC 842, the incentive was recorded as a component of lease incentives on the condensed consolidated balance sheets and was amortized as a reduction in rent expense on a straight-line basis over the term of the lease. Upon adoption of the new standard the unamortized balance of the lease incentive as of January 1, 2019 was reclassified as a reduction to the initial recognition of the right-of-use asset related to this lease. In connection with this lease agreement, the Company paid a security deposit of $281,000, which is recorded as a component of both prepaid expenses and other current assets and other assets in the condensed consolidated balance sheets.

Operating leases are amortized over the lease term and included in costs and expenses in the condensed consolidated statement of operations and comprehensive loss. Variable lease costs are recognized in costs and expenses in the condensed consolidated statement of operations and comprehensive loss as incurred.

Finance Leases

In October 2015, the Company signed a $10.0 million Credit Facility (the “Credit Facility”) to fund capital equipment needs. As one of the conditions of the Term Loan Agreement, the Credit Facility is capped at a maximum of $5.0 million. Under the Credit Facility, the lender will fund capital equipment purchases presented by the Company. The Company will repay the amounts borrowed in 36 equal monthly installments from the date of the amount funded. At the end of the 36 month lease term, the Company has the option to (a) repurchase the leased equipment at the lesser of fair market value or 10% of the original equipment value, (b) extend the applicable lease for a specified period of time, which will not be less than one year, or (c) return the leased equipment to the lessor.

In April 2016 and June 2016, the Company completed the first two draws under the Credit Facility of $2.1 million and $2.5 million, respectively. The Company made monthly payments of $67,000 under the first draw and $79,000 under the second draw. The borrowings under the Credit Facility are treated as finance leases and are included in property and equipment on the balance sheet. The amortization of the assets conveyed under the Credit Facility is included as a component of depreciation expense. During the three months ended September 30, 2019, the Company repurchased the equipment for $0.3 million in accordance with the terms of the Credit Facility.

The following table summarizes the effect of operating and finance lease costs in the Company’s condensed consolidated statement of operations and comprehensive loss (in thousands):

Lease cost	Three months ended September 30, 2019		Nine months ended September 30, 2019
Finance lease cost:
Amortization of right-of-use assets	$	—	$	235
Interest on lease liabilities		—		36
Operating lease cost		499		1,497
Variable lease cost		163		483
Total lease cost	$	662	$	2,251

The following table summarizes supplemental information for the Company’s finance and operating leases:

Other information

Nine months ended

September 30, 2019

Weighted-average remaining lease term - operating leases (in years)

2.1 years

Weighted-average discount rate - operating leases

11.9

The minimum lease payments for the next five years and thereafter is expected to be as follows (in thousands):

	September 30, 2019
Maturity of lease liabilities	Operating Leases
2019 (excluding the 9 months ended September 30, 2019)	$	566
2020		2,314
2021		1,951
2022		23
2023		—
Thereafter		—
Total lease payments	$	4,854
Less: effect of discounting		(551	)
Present value of lease liabilities	$	4,303

The following table summarizes the presentation of the Company’s operating leases in its condensed consolidated balance sheets (in thousands):

Leases	Classification	September 30, 2019
Assets
Operating lease assets	Operating lease assets		3,740
Total lease assets		$	3,740

Liabilities
Current
Operating	Accrued expenses and other current liabilities	$	1,913
Noncurrent
Operating	Noncurrent operating lease liabilities		2,390
Total lease liabilities		$	4,303

Under ASC 840, future minimum non-cancelable lease payments under the Company’s operating leases as of December 31, 2018 were as follows (in thousands):

Year ended December 31,
2019	$	2,225
2020		2,277
2021		1,926
	$	6,428

Under ASC 840, rent expense for the years ended December 31, 2018, and 2017 was $2.0 million, and $1.9 million, respectively.

Commitments and Contingencies

9 Months Ended

Sep. 30, 2019

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

13. Commitments and Contingencies

Leases

Refer to Note 12, Leases, for discussion of the commitments associated with the Company’s leases.

License Agreement

In 2006, the Company entered into a license agreement with a third party, pursuant to which the third party granted the Company an exclusive, worldwide, sublicenseable license under certain patent rights to make, use, import and commercialize products and processes for diagnostic, industrial and research and development purposes. The Company agreed to pay an annual license fee ranging from $5,000 to $25,000 for the royalty‑bearing license to certain patents. The Company also issued a total of 84,678 shares of common stock pursuant to the agreement in 2006 and 2007, which were recorded at fair value at the date of issuance. The Company is required to pay royalties on net sales of products and processes that are covered by patent rights licensed under the agreement at a percentage ranging between 0.5% - 3.5%, subject to reductions and offsets in certain circumstances, as well as a royalty on net sales of products that the Company sublicenses at 10% of specified gross revenue. Royalties for the nine months ended September 30, 2019 and 2018 were immaterial.

Severance Agreement

On July 30, 2019, the Company announced that founding CEO John McDonough was named Executive Chairman of the Board, effective immediately, and that the Company was undertaking a national search for a new CEO. Once that candidate is identified, Mr. McDonough will become non-executive Chairman of the Board. Mr. McDonough will continue in the role of CEO and Executive Chairman until his successor is in place. A successor has not been named. Transition payments and health benefits under the terms of the agreement are estimated to be approximately $1.0 million, which will be paid over the 15 month period following the successor’s start date, and will be classified as selling, general and administrative expense over the anticipated period of the national search, estimated to be 8 months. Such expenses were immaterial for the three and nine months ended September 30, 2019.

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Basis of Presentation

Unaudited Interim Financial Information

Segment Information

Geographic Information

As of September 30, 2019 and December 31, 2018, the Company had outstanding receivables of $0.5 million and $0.9 million, respectively, from customers located outside of the U.S.

Net Loss Per Share

Guarantees

Leases

The Company made the policy election to not separate lease and non-lease components. Each lease component and the related non-lease components are accounted for together as a single component.

Revenue Recognition


Most of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. Excluded from the transaction price are sales tax and other similar taxes which are presented on a net basis.

Fees paid to member-owned group purchasing organizations (“GPOs”) are deducted from related product revenues.

Disaggregation of Revenue

	Three months ended, September 30,				Nine months ended, September 30,
	2019		2018		2019		2018
Product Revenue
Instruments	$	543	$	504	$	1,540	$	1,213
Consumables		604		608		2,054		1,929
Instrument rentals		30		106		171		344
Total Product Revenue		1,177		1,218		3,765		3,486
Research Revenue		56		1,248		269		5,222
Contribution Revenue		444		—		1,232		—
Total Revenue	$	1,677	$	2,466	$	5,266	$	8,708

Remaining Performance Obligations

Significant Judgments

Contract Assets and Liabilities

The Company did not record any contract assets at September 30, 2019 and December 31, 2018.

Cost to Obtain and Fulfill a Contract

Cost of Product Revenue

Research and Development Costs

Recent Accounting Standards

Accounting Standards Adopted

Accounting Standards Issued, Not Adopted

Emerging Growth Company Status

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Disaggregation of Revenue by Major Source

The following table disaggregates our revenue by major source (in thousands):

	Three months ended, September 30,				Nine months ended, September 30,
	2019		2018		2019		2018
Product Revenue
Instruments	$	543	$	504	$	1,540	$	1,213
Consumables		604		608		2,054		1,929
Instrument rentals		30		106		171		344
Total Product Revenue		1,177		1,218		3,765		3,486
Research Revenue		56		1,248		269		5,222
Contribution Revenue		444		—		1,232		—
Total Revenue	$	1,677	$	2,466	$	5,266	$	8,708

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis

	Balance at September 30, 2019		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash	$	11,926	$	11,926	$	—	$	—
Money market funds		4,287		4,287		—		—
Restricted cash		180		180		—		—
	$	16,393	$	16,393	$	—	$	—


Liabilities:
Derivative liability	$	2,603	$	—	$	—	$	2,603
	$	2,603	$	—	$	—	$	2,603

	Balance at December 31, 2018		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash	$	6,868	$	6,868	$	—	$	—
Money market funds		43,937		43,937		—		—
Restricted cash		180		180		—		—
	$	50,985	$	50,985	$	—	$	—


Liabilities:
Derivative liability	$	2,142	$	—	$	—	$	2,142
	$	2,142	$	—	$	—	$	2,142

Roll-Forward of Fair Value of Derivative Liability

The following table provides a roll-forward of the fair value of the derivative liability (in thousands):

Balance at December 31, 2018	$	2,142
Change in fair value of derivative liability, recorded as interest expense		461
Balance at September 30, 2019	$	2,603

Supplemental Balance Sheet Information (Tables)

9 Months Ended

Sep. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Accounts Receivable

Accounts receivable consists of the following (in thousands):

	September 30, 2019		December 31, 2018
Accounts receivable	$	873	$	1,786
Unbilled receivables		700		—
Total accounts receivable	$	1,573	$	1,786

Schedule of Inventory

Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis and are comprised of the following (in thousands):

	September 30, 2019		December 31, 2018
Raw materials	$	1,903	$	639
Work-in-process		1,586		1,713
Finished goods		621		325
Total inventories, net	$	4,110	$	2,677

Schedule of Property and Equipment

Property and equipment consists of the following (in thousands):

	September 30, 2019			December 31, 2018
Office and computer equipment	$	409		$	409
Software		762			751
Laboratory equipment		4,747			4,636
Furniture		194			200
Manufacturing equipment		672			695
Manufacturing tooling and molds		255			255
T2-owned instruments and components		6,879			6,796
Leasehold improvements		3,497			3,437
Construction in progress		1,698			1,443
		19,113			18,622
Less accumulated depreciation and amortization		(12,799	)		(11,307	)
Property and equipment, net	$	6,314		$	7,315

Components of Accrued Expenses

Accrued expenses consist of the following (in thousands):

	September 30, 2019		December 31, 2018
Accrued payroll and compensation	$	2,809	$	2,940
Accrued research and development expenses		297		359
Accrued professional services		291		576
Operating lease liabilities		1,913		—
Other accrued expenses		3,490		2,198
Total accrued expenses and other current liabilities	$	8,800	$	6,073

Notes Payable (Tables)

9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Schedule of Debt

Future principal payments on the notes payable are as follows (in thousands):

	September 30, 2019			December 31, 2018
Term loan agreement, net of deferred issuance costs of $2.0 million and $1.8 million, respectively	$	42,258		$	41,419
Equipment lease credit facility, net of immaterial deferred issuance costs		—			954
Total notes payable		42,258			42,373
Less: current portion of notes payable		(42,258	)		(42,373	)
Notes payable, net of current portion	$	—		$	—

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Stock Option Activity

The following is a summary of option activity under the Stock Incentive Plans and Inducement Plan (in thousands, except share and per share amounts):

	Number of Shares			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (In years)		Aggregate Intrinsic Value
Outstanding at December 31, 2018		4,241,833		$	6.98		7.02	$	471
Granted		2,683,200			2.11
Exercised		(938	)		2.68
Forfeited		(373,388	)		5.28
Cancelled		(119,270	)		7.81
Outstanding at September 30, 2019		6,431,437		$	5.03		7.46	$	2,148
Exercisable at September 30, 2019		2,996,830		$	7.30		5.35	$	257
Vested or expected to vest at September 30, 2019		5,740,731		$	5.28		7.23	$	1,791

Schedule of Estimated Assumptions Used to Calculate Weighted-Average Grant Date Fair Value of Options Granted

	Nine Months Ended
	September 30,
	2019			2018
Weighted-average risk-free interest rate		1.98	%		2.66	%
Expected dividend yield		—	%		—	%
Expected volatility		78	%		68	%
Expected terms	6.0 years			6.0 years

Schedule of Nonvested Restricted Stock Units Activity

The following is a summary of restricted stock unit activity under the 2014 Plan (in thousands, except share and per share amounts):

	Number of Shares			Weighted-Average Grant Date Fair Value
Nonvested at December 31, 2018		1,198,634			5.04
Granted		589,142			3.23
Vested		(189,129	)		6.41
Forfeited		(286,889	)		4.41
Cancelled		—			—
Nonvested at September 30, 2019		1,311,758			4.17

Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company's Results of Operations

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Cost of product revenue	$	7	$	23	$	295	$	408
Research and development		283		409		975		1,271
Selling, general and administrative		862		1,601		3,216		5,561
Total stock-based compensation expense	$	1,152	$	2,033	$	4,486	$	7,240

Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

	Three and Nine Months Ended September 30,
	2019		2018
Options to purchase common shares		6,431,437		4,236,595
Restricted stock units		1,311,758		1,202,123
Warrants to purchase common stock		1,097,249		528,958
Total		8,840,444		5,967,676

Leases (Tables)

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Schedule of Lease Cost

The following table summarizes the effect of operating and finance lease costs in the Company’s condensed consolidated statement of operations and comprehensive loss (in thousands):

Lease cost	Three months ended September 30, 2019		Nine months ended September 30, 2019
Finance lease cost:
Amortization of right-of-use assets	$	—	$	235
Interest on lease liabilities		—		36
Operating lease cost		499		1,497
Variable lease cost		163		483
Total lease cost	$	662	$	2,251

Schedule of Other Information Related to Leases

The following table summarizes supplemental information for the Company’s finance and operating leases:

Other information

Nine months ended

September 30, 2019

Weighted-average remaining lease term - operating leases (in years)

2.1 years

Weighted-average discount rate - operating leases

11.9

Schedule of Maturity of Lease Liabilities

The minimum lease payments for the next five years and thereafter is expected to be as follows (in thousands):

	September 30, 2019
Maturity of lease liabilities	Operating Leases
2019 (excluding the 9 months ended September 30, 2019)	$	566
2020		2,314
2021		1,951
2022		23
2023		—
Thereafter		—
Total lease payments	$	4,854
Less: effect of discounting		(551	)
Present value of lease liabilities	$	4,303

Summary of Lease Assets and Liabilities

The following table summarizes the presentation of the Company’s operating leases in its condensed consolidated balance sheets (in thousands):

Leases	Classification	September 30, 2019
Assets
Operating lease assets	Operating lease assets		3,740
Total lease assets		$	3,740

Liabilities
Current
Operating	Accrued expenses and other current liabilities	$	1,913
Noncurrent
Operating	Noncurrent operating lease liabilities		2,390
Total lease liabilities		$	4,303

Schedule of Future Minimum Lease Payments under the Company’s Operating Leases

Under ASC 840, future minimum non-cancelable lease payments under the Company’s operating leases as of December 31, 2018 were as follows (in thousands):

Year ended December 31,
2019	$	2,225
2020		2,277
2021		1,926
	$	6,428

Summary of Significant Accounting Policies - Additional Information (Detail)		3 Months Ended		9 Months Ended
	Jan. 01, 2019 USD ($) lease_arrangement	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2019 USD ($) Segment	Sep. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)
Product Information [Line Items]
Number of operating segments \| Segment				1
Total revenue		$ 1,677,000	$ 2,466,000	$ 5,266,000	$ 8,708,000
Outstanding receivable		1,573,000		1,573,000		$ 1,786,000
Aggregate amount of transaction price allocated to remaining performance obligations for contracts with original duration greater than one year		3,500,000		$ 3,500,000
Remaining performance obligation, expected timing of satisfaction				The Company expects to recognize revenue on the remaining performance obligations over the next two years.
Contract assets		0		$ 0		0
Contract liabilities		600,000		600,000		600,000
Revenue recognized relating to contract liabilities		100,000		400,000
Costs to obtain or fulfill contract capitalized		0		0
Operating lease liabilities		4,303,000		4,303,000
Right-of-use assets		3,740,000		3,740,000
Co Development Partnership Agreement [Member] \| CARB-X [Member]
Product Information [Line Items]
Total revenue		100,000	400,000	$ 900,000	900,000
Accounting Standards Update 2016-02 [Member]
Product Information [Line Items]
Maximum short-term lease exception period				12 months
Number of operating lease arrangements \| lease_arrangement	8
Number of finance lease arrangements \| lease_arrangement	2
Operating lease liabilities	$ 5,600,000
Right-of-use assets	4,800,000
Accrued rent liability	$ 800,000
T2 Dx [Member]
Product Information [Line Items]
Maintenance Services period (in years)				1 year
Additional period for Maintenance Service option (in years)				1 year
Constrained Revenue [Member]
Product Information [Line Items]
Aggregate amount of transaction price allocated to remaining performance obligations for contracts with original duration greater than one year		3,000,000		$ 3,000,000
Instrument Rentals [Member]
Product Information [Line Items]
Total revenue		30,000	106,000	171,000	344,000
Lease revenue		100,000		$ 200,000
Maximum [Member]
Product Information [Line Items]
Original expected period of contracts for which value of unsatisfied performance obligations not to be disclosed				1 year
Minimum [Member]
Product Information [Line Items]
Aggregate amount of transaction price allocated to remaining performance obligations, original duration				1 year
Non-US [Member]
Product Information [Line Items]
Total revenue		600,000	$ 600,000	$ 1,800,000	$ 1,400,000
Outstanding receivable		$ 500,000		$ 500,000		$ 900,000
Revenue [Member] \| Geographic Concentration Risk [Member] \| Non-US [Member]
Product Information [Line Items]
Total revenue (as a percent)		36.00%	25.00%	34.00%	16.00%
Revenue [Member] \| Geographic Concentration Risk [Member] \| Non-US [Member] \| Maximum [Member]
Product Information [Line Items]
Total revenue (as a percent)		10.00%		10.00%	10.00%
Customer One [Member] \| Revenue [Member] \| Geographic Concentration Risk [Member] \| Non-US [Member] \| Maximum [Member]
Product Information [Line Items]
Total revenue (as a percent)			10.00%

Summary of Significant Accounting Policies - Disaggregation of Revenue by Major Resource (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation Of Revenue [Line Items]
Total revenue	$ 1,677	$ 2,466	$ 5,266	$ 8,708
Product Instruments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	543	504	1,540	1,213
Total Product Revenue [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	1,177	1,218	3,765	3,486
Product Consumables [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	604	608	2,054	1,929
Research [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	56	1,248	269	5,222
Instrument Rentals [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	30	$ 106	171	$ 344
Contribution Revenue [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 444		$ 1,232

Fair Value Measurements - Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis (Detail) - Estimate of Fair Value Measurement [Member] - Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Assets:
Restricted cash	$ 180	$ 180
Total assets	16,393	50,985
Liabilities:
Derivative liability	2,603	2,142
Total Liabilities	2,603	2,142
Cash [Member]
Assets:
Cash	11,926	6,868
Money Market Funds [Member]
Assets:
Cash	4,287	43,937
Level 1 [Member]
Assets:
Restricted cash	180	180
Total assets	16,393	50,985
Level 1 [Member] \| Cash [Member]
Assets:
Cash	11,926	6,868
Level 1 [Member] \| Money Market Funds [Member]
Assets:
Cash	4,287	43,937
Level 3 [Member]
Liabilities:
Derivative liability	2,603	2,142
Total Liabilities	$ 2,603	$ 2,142

Fair Value Measurements - Additional Information (Detail) - USD ($)		1 Months Ended		6 Months Ended	9 Months Ended
	Dec. 31, 2018	Sep. 30, 2019	Mar. 31, 2019	Aug. 31, 2019	Sep. 30, 2019
Certificates of deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Certificates of deposit classified as restricted cash	$ 200,000	$ 200,000			$ 200,000
CRG [Member] \| Term Loan Agreement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Additional interest rate, event of default (as a percent)					4.00%
Debt instrument covenant compliance revenue targeted for fiscal year	95,000,000	4,000,000	$ 9,000,000	$ 9,000,000
Derivative liability	$ 2,100,000	$ 2,600,000			$ 2,600,000
CRG [Member] \| Term Loan Agreement [Member] \| Contingent Interest Beginning in 2020 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent payment of interest rate					4.00%
CRG [Member] \| Term Loan Agreement [Member] \| Contingent Interest Beginning in 2020 [Member] \| Measurement Input, Discount Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair value of discount rate					70.00%
CRG [Member] \| Term Loan Agreement [Member] \| Contingent Interest Beginning in 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent payment of interest rate					4.00%
CRG [Member] \| Term Loan Agreement [Member] \| Contingent Interest Beginning in 2021 \| Measurement Input, Discount Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair value of discount rate					30.00%

Fair Value Measurements - Roll-Forward of Fair Value of Derivative Liability (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of derivative liability, recorded as interest expense	$ 461	$ (175)
Probability-Weighted Discounted Cash Flow Model [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at December 31, 2018	2,142
Change in fair value of derivative liability, recorded as interest expense	461
Balance at September 30, 2019	$ 2,603

Supplemental Balance Sheet Information - Schedule of Accounts Receivable (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accounts receivable	$ 873	$ 1,786
Unbilled receivables	700
Total accounts receivable	$ 1,573	$ 1,786

Supplemental Balance Sheet Information - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 1,903	$ 639
Work-in-process	1,586	1,713
Finished goods	621	325
Total inventories, net	$ 4,110	$ 2,677

Supplemental Balance Sheet Information - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 19,113	$ 18,622
Less accumulated depreciation and amortization	(12,799)	(11,307)
Property and equipment, net	6,314	7,315
Office and Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	409	409
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	762	751
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	4,747	4,636
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	194	200
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	672	695
Manufacturing Tooling and Molds [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	255	255
T2-Owned Instruments and Components [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	6,879	6,796
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,497	3,437
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,698	$ 1,443

Supplemental Balance Sheet Information - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Supplemental Balance Sheet Information [Line Items]
Raw materials and work-in-process inventory	$ 600,000		$ 600,000		$ 300,000
Depreciation and amortization	500,000	$ 600,000	1,694,000	$ 1,862,000
Property and equipment, net	6,314,000		6,314,000		7,315,000
Property and equipment, gross	19,113,000		19,113,000		18,622,000
Accumulated depreciation and amortization for property and equipment	12,799,000		12,799,000		11,307,000
Transfer from other liabilities to accrued expenses and other current liabilities related to fee from debt			$ 2,100,000		1,400,000
T2 Owned Instruments in Service [Member]
Supplemental Balance Sheet Information [Line Items]
Estimated useful lives (in years)			5 years
T2 Owned Instruments in Service [Member] \| Product [Member]
Supplemental Balance Sheet Information [Line Items]
Depreciation expense recorded as a component of cost of product revenue	200,000	$ 200,000	$ 600,000	$ 700,000
Finance Leases Assets [Member]
Supplemental Balance Sheet Information [Line Items]
Property and equipment, net	$ 0		$ 0
Property and equipment, gross					3,600,000
Accumulated depreciation and amortization for property and equipment					$ 2,600,000

Supplemental Balance Sheet Information - Components of Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accrued Liabilities Current [Abstract]
Accrued payroll and compensation	$ 2,809	$ 2,940
Accrued research and development expenses	297	359
Accrued professional services	291	576
Operating lease liabilities	1,913
Other accrued expenses	3,490	2,198
Total accrued expenses and other current liabilities	$ 8,800	$ 6,073

Notes Payable - Schedule of Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Debt Instrument
Total notes payable	$ 42,258	$ 42,373
Less: current portion of notes payable	(42,258)	(42,373)
Medium-term Notes [Member] \| Term Loan Agreement [Member]
Debt Instrument
Total notes payable	$ 42,258	41,419
Line of Credit [Member] \| Equipment Lease Credit Facility [Member]
Debt Instrument
Total notes payable		$ 954

Notes Payable - Term Loan Agreement - Additional Information (Detail) - USD ($)			1 Months Ended			6 Months Ended	9 Months Ended		24 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2019	Mar. 31, 2019	Dec. 31, 2016	Aug. 31, 2019	Dec. 31, 2022	Sep. 30, 2019	Jan. 01, 2022	Jan. 01, 2021
Common Stock [Member]
Debt Instrument
Number of shares issuable for warrants outstanding (in shares)			568,291		528,958			568,291
Exercise price of warrants			$ 1.55	$ 4.35	$ 8.06			$ 1.55
CRG [Member] \| Term Loan Agreement [Member]
Debt Instrument
Proceeds from issuance of long-term debt					$ 40,000,000
Debt term (in years)					6 years
Debt instrument, term of interest-only payments (in years)					4 years
Final fee as a percentage of the principal outstanding (as a percent)			10.00%		8.00%	8.00%		10.00%
Annual fixed rate (as a percent)					11.50%
Deferred interest rate (as a percent)					3.50%
Debt instrument, prepayment fee term (in years)					5 years
Debt instrument covenant compliance revenue targeted for fiscal year		$ 95,000,000	$ 4,000,000	$ 9,000,000		$ 9,000,000
Additional interest rate, event of default (as a percent)								4.00%
Derivative liability		$ 2,100,000	$ 2,600,000					$ 2,600,000
CRG [Member] \| Term Loan Agreement [Member] \| Scenario Forecast [Member]
Debt Instrument
Debt instrument, quarterly principal payment							$ 12,000,000
Debt instrument covenant compliance revenue targeted for fiscal year	$ 140,000,000								$ 43,000,000	$ 15,000,000

Notes Payable - Equipment Lease Credit Facility - Additional Information (Detail) - Finance Lease Obligations [Member]	1 Months Ended			3 Months Ended
	Jun. 30, 2016 USD ($) Draw	Apr. 30, 2016 USD ($)	Oct. 31, 2015 USD ($)	Sep. 30, 2019 USD ($)
Debt Instrument
Initial borrowing capacity			$ 10,000,000
Maximum borrowings available (up to)			$ 5,000,000
Debt term (in months)			36 months
Repurchase price as percentage of original equipment value that the equipment under lease may be repurchased by lessee			10.00%
Minimum lease period to extend lease (in years)			1 year
Amount of draw	$ 2,500,000	$ 2,100,000
Amount of monthly payment	$ 79,000	$ 67,000
Number of draws \| Draw	2
Repurchase of equipment				$ 300,000

Stockholders' Equity - Additional Information (Detail) - USD ($)				3 Months Ended
	Jul. 30, 2019	Jul. 29, 2019	Jun. 04, 2018	Sep. 30, 2019
Sales Agreement [Member] \| Canaccord [Member]
Class Of Stock [Line Items]
Sale of common stock authorized, amount	$ 30,000,000
Percentage of agent service fee	3.00%
Number of shares issued/sold				1,679,387
Proceeds from issuance of common stock				$ 1,900,000
Purchase Agreement [Member] \| Lincoln Park [Member]
Class Of Stock [Line Items]
Sale of common stock authorized, amount		$ 30,000,000
Number of shares issued/sold		413,349
Effective period for sale of common stock		36 months
Maximum number of shares issue per business day		200,000
Maximum amount of shares to be issue per business day		$ 2,000,000
Public Offering [Member]
Class Of Stock [Line Items]
Number of shares issued/sold			7,015,000
Proceeds from issuance of common stock			$ 52,600,000
Sale price of stock (in dollars per share)			$ 7.50
Proceeds from issuance of common stock after underwriters discount and expenses			$ 49,200,000

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Mar. 31, 2018
Share-Based Compensation
Fair value of vested stock options			$ 2,400	$ 2,300
Stock-based compensation expense	$ 1,152	$ 2,033	$ 4,486	7,240
T2-Owned Instruments and Components [Member]
Share-Based Compensation
Stock-based compensation expense				300
Restricted Stock Units [Member]
Share-Based Compensation
Weighted-average period			2 years 1 month 17 days
Unrecognized compensation cost related to unvested stock options	$ 1,600		$ 1,600
2006 Stock Option Plan [Member] \| Stock Options [Member]
Share-Based Compensation
Shares available for grant	407,870		407,870
2014 Stock Option Plan [Member] \| Stock Options [Member]
Share-Based Compensation
Shares available for future issuance under stock incentive plan	823,529		823,529
Percentage of common shares outstanding	4.00%		4.00%
Shares available for grant	407,870		407,870
2014 Stock Option Plan [Member] \| Restricted Stock Units [Member]
Share-Based Compensation
Restricted stock units vested			189,129
Restricted stock units granted			589,142
Inducement Award Plan [Member]
Share-Based Compensation
Shares available for grant	752,708		752,708
Shares available for authorization						1,625,000
2006 and 2014 Stock Option Plans [Member] \| Stock Options [Member]
Share-Based Compensation
Aggregate fair value of options granted			$ 3,800	$ 5,500
Unrecognized compensation cost related to non-vested stock options	$ 6,500		$ 6,500
Weighted-average period			2 years 8 months 12 days
2006 and 2014 Stock Option Plans and Inducement Plan [Member] \| Stock Options [Member]
Share-Based Compensation
Weighted average fair value of options granted			$ 1.40	$ 3.55
2006 and 2014 Stock Option Plans and Inducement Plan [Member] \| Restricted Stock Units [Member]
Share-Based Compensation
Aggregate fair value of restricted stock units granted			$ 1,900
2006 and 2014 Stock Option Plans and Inducement Plan [Member] \| Restricted Stock Units [Member] \| Restricted Stock Units Vested, Reflected As Outstanding Shares [Member]
Share-Based Compensation
Restricted stock units vested					78,172
2006 and 2014 Stock Option Plans and Inducement Plan [Member] \| Restricted Stock Units [Member] \| Restricted Stock Units Vested, Not Reflected As Outstanding Shares [Member]
Share-Based Compensation
Restricted stock units vested					73,172
2006 and 2014 Stock Option Plans and Inducement Plan [Member] \| Restricted Stock Units with Market Condition [Member]
Share-Based Compensation
Restricted stock units granted			755,168
Compensation Cost	$ 200	$ 900	$ 1,000	$ 3,600
Maximum [Member] \| 2006 Stock Option Plan [Member] \| Stock Options [Member]
Share-Based Compensation
Expiration period			10 years
Vesting period			4 years
Maximum [Member] \| 2014 Stock Option Plan [Member] \| Stock Options [Member]
Share-Based Compensation
Expiration period			10 years
Vesting period			4 years

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - 2006 and 2014 Stock Option Plans and Inducement Plan [Member] - Stock Options [Member] - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Share-Based Compensation
Number of Shares Outstanding, beginning of the period	4,241,833
Number of Shares, Granted	2,683,200
Number of Shares, Exercised	(938)
Number of Shares, Forfeited	(373,388)
Number of Shares, Cancelled	(119,270)
Number of Shares Outstanding, end of the period	6,431,437	4,241,833
Number of Shares, Exercisable	2,996,830
Number of Shares, Vested or expected to vest	5,740,731
Weighted-Average Exercise Price Per Share Outstanding, beginning of the period	$ 6.98
Weighted-Average Exercise Price Per Share, Granted	2.11
Weighted-Average Exercise Price Per Share, Exercised	2.68
Weighted-Average Exercise Price Per Share, Forfeited	5.28
Weighted-Average Exercise Price Per Share, Cancelled	7.81
Weighted-Average Exercise Price Per Share Outstanding, end of the period	5.03	$ 6.98
Weighted-Average Exercise Price Per Share, Exercisable	7.30
Weighted-Average Exercise Price Per Share, Vested or expected to vest	$ 5.28
Weighted-Average Remaining Contractual Term, Outstanding	7 years 5 months 15 days	7 years 7 days
Weighted-Average Remaining Contractual Term, Exercisable	5 years 4 months 6 days
Weighted-Average Remaining Contractual Term, Vested or expected to vest	7 years 2 months 23 days
Aggregate Intrinsic Value, Outstanding, beginning of the period	$ 471
Aggregate Intrinsic Value Outstanding, end of the period	2,148	$ 471
Aggregate Intrinsic Value, Exercisable	257
Aggregate Intrinsic Value, Vested or expected to vest	$ 1,791

Stock-Based Compensation - Schedule of Estimated Assumptions Used to Calculate Weighted-Average Grant Date Fair Value of Options Granted (Detail) - Stock Options [Member] - 2006 and 2014 Stock Option Plans and Inducement Plan [Member]	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-Based Compensation
Weighted-average risk-free interest rate	1.98%	2.66%
Expected volatility	78.00%	68.00%
Expected terms	6 years	6 years

Stock-Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Detail) - 2014 Stock Option Plan [Member] - Restricted Stock Units [Member]	9 Months Ended
	Sep. 30, 2019 $ / shares shares
Share-Based Compensation
Number of Shares, Nonvested restricted shares at the beginning of the period \| shares	1,198,634
Number of Shares, Restricted shares granted \| shares	589,142
Number of Shares, Restricted shares vested \| shares	(189,129)
Number of Shares, Restricted shares forfeited \| shares	(286,889)
Number of Shares, Nonvested restricted shares at the end of the period \| shares	1,311,758
Weighted-Average Grant Date Fair Value, Nonvested restricted shares at the beginning of the period	$ 5.04
Weighted-Average Grant Date Fair Value, Granted	3.23
Weighted-Average Grant Date Fair Value, Vested	6.41
Weighted-Average Grant Date Fair Value, Forfeited	4.41
Weighted-Average Grant Date Fair Value, Cancelled	0
Weighted-Average Grant Date Fair Value, Nonvested restricted shares at the end of the period	$ 4.17

Warrants - Additional Information (Detail) - Common Stock [Member] - USD ($) $ / shares in Units, $ in Millions		1 Months Ended
	Aug. 31, 2019	Sep. 30, 2019	Mar. 31, 2019	Dec. 31, 2016
Class of Warrant or Right [Line Items]
Number of shares issuable for warrants outstanding		568,291		528,958
Exercise price of warrants		$ 1.55	$ 4.35	$ 8.06
Fair market value of amended warrants	$ 0.9	$ 0.1
Incremental fair value of warrants adjustment	$ 0.1	$ 0.7

Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net loss per share	8,840,444	5,967,676	8,840,444	5,967,676
Options to Purchase Common Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net loss per share	6,431,437	4,236,595	6,431,437	4,236,595
Restricted Stock Units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net loss per share	1,311,758	1,202,123	1,311,758	1,202,123
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net loss per share	1,097,249	528,958	1,097,249	528,958

Co-Development Agreements - Additional Information (Detail)			1 Months Ended		3 Months Ended		9 Months Ended
	Nov. 01, 2016 specie	Sep. 21, 2016 USD ($)	Jan. 31, 2019 USD ($)	Mar. 31, 2018 USD ($) specie	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					$ 1,677,000	$ 2,466,000	$ 5,266,000	$ 8,708,000
Co Development Partnership Agreement [Member] \| Canon U.S. Life Sciences Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					100,000	200,000	200,000	1,500,000
Co Development Partnership Agreement [Member] \| Allergan Sales [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					0	700,000	0	2,900,000
Number of additional bacteria species added to existing product candidate \| specie	1
Co Development Partnership Agreement [Member] \| CARB-X [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					100,000	$ 400,000	900,000	$ 900,000
Number of additional bacteria species added to existing product candidate \| specie				20
Co Development Partnership Agreement [Member] \| CARB-X [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate consideration receivable				$ 2,000,000
Collaborative arrangement reimbursement amount			$ 900,000	1,100,000			900,000
Milestone payment				$ 900,000
Co Development Partnership Agreement [Member] \| Biomedical Advanced Research and Development Authority [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					300,000		300,000
Initial value of consideration receivable					6,000,000		6,000,000
Co Development Partnership Agreement [Member] \| Biomedical Advanced Research and Development Authority [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate consideration receivable					$ 69,000,000		$ 69,000,000
Private Placement [Member] \| Canon U S A Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from sale of shares in related party		$ 39,700,000
Percentage of outstanding shares at date of sale		19.90%

Leases - Additional Information (Detail)		1 Months Ended							3 Months Ended	9 Months Ended	12 Months Ended
Leases - Additional Information (Detail)	Sep. 30, 2017	Aug. 31, 2018	Mar. 31, 2017	Jun. 30, 2016 USD ($) Draw	Apr. 30, 2016 USD ($)	Oct. 31, 2015 USD ($)	Apr. 30, 2015	Nov. 30, 2014 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Jan. 31, 2018 USD ($)	Jan. 11, 2011 USD ($)
Leases [Line Items]
Right-of-use assets									$ 3,740,000	$ 3,740,000
Lease liabilities									4,303,000	4,303,000
Rent expenses											$ 2,000,000	$ 1,900,000
Finance Lease Obligations [Member]
Leases [Line Items]
Initial borrowing capacity						$ 10,000,000
Maximum borrowings available (up to)						$ 5,000,000
Debt term (in months)						36 months
Repurchase price as percentage of original equipment value that the equipment under lease may be repurchased by lessee						10.00%
Minimum lease period to extend lease (in years)						1 year
Amount of draw				$ 2,500,000	$ 2,100,000
Amount of monthly payment				$ 79,000	$ 67,000
Number of draws \| Draw				2
Repurchase of equipment									300,000
Operating Lease Entered into November 2014 [Member] \| License Agreement [Member] \| Office Space [Member]
Leases [Line Items]
Lease expiration date	Dec. 31, 2021						Dec. 31, 2017
Security deposit								$ 50,000
Office Space, Laboratory Space, and Equipment [Member]
Leases [Line Items]
Right-of-use assets									0	0
Lease liabilities									$ 0	$ 0
Maximum lease period to not recognize right of use assets or lease liabilities										12 months
Office and Laboratory Space [Member] \| Operating Lease Entered into August 2010 [Member]
Leases [Line Items]
Lease expiration date			Dec. 31, 2021
Security deposit													$ 180,000	$ 400,000
Office, Laboratory and Manufacturing Space [Member] \| Operating Lease Entered into May 2013 [Member]
Leases [Line Items]
Lease expiration date		Dec. 31, 2020
Laboratory Space [Member] \| Operating Lease Entered into November 2014 [Member]
Leases [Line Items]
Security deposit								$ 281,000
Term of lease								6 years
Space build-out costs paid								$ 1,400,000
Space build-out costs to be paid by landlord								$ 2,200,000

Leases - Schedule of Lease Cost (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Finance lease cost:
Amortization of right-of-use assets		$ 235
Interest on lease liabilities		36
Operating lease cost	$ 499	1,497
Variable lease cost	163	483
Total lease cost	$ 662	$ 2,251

Leases - Schedule of Maturity of Lease Liabilities (Detail) $ in Thousands	Sep. 30, 2019 USD ($)
Maturity of operating leases liabilities
2019 (excluding the 9 months ended September 30, 2019)	$ 566
2020	2,314
2021	1,951
2022	23
Total lease payments	4,854
Less: effect of discounting	(551)
Present value of lease liabilities	$ 4,303

Leases - Summary of Lease Assets and Liabilities (Detail) $ in Thousands	Sep. 30, 2019 USD ($)
Schedule Of Lease Assets And Liabilities [Abstract]
Operating lease assets	$ 3,740
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	ttoo:OperatingLeaseAssetsMember
Operating lease liabilities, Current	$ 1,913
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	ttoo:AccruedExpensesAndOtherCurrentLiabilitiesMember
Operating lease liabilities, Noncurrent	$ 2,390
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	ttoo:NoncurrentOperatingLeaseLiabilitiesMember
Total lease liabilities	$ 4,303

Leases - Future Minimum Lease Payments (Detail) $ in Thousands	Dec. 31, 2018 USD ($)
Future minimum lease payments
2019	$ 2,225
2020	2,277
2021	1,926
Total	$ 6,428

Commitments and Contingencies - Additional Information (Details) - USD ($)		9 Months Ended	24 Months Ended
	Jul. 30, 2019	Sep. 30, 2019	Dec. 31, 2007	Dec. 31, 2006
Operating Leased Assets [Line Items]
Shares issued			84,678
Royalty on net sales sublicensing gross revenue		10.00%
Selling, General and Administrative [Member]
Operating Leased Assets [Line Items]
Transition payments and health benefits	$ 1,000,000
Payment period on transition and health benefits	15 months
Anticipated period on national search	8 months
Minimum [Member]
Operating Leased Assets [Line Items]
Annual license fee payable				$ 5,000
Percentage of royalty on net sales		0.50%
Maximum [Member]
Operating Leased Assets [Line Items]
Annual license fee payable				$ 25,000
Percentage of royalty on net sales		3.50%

Notes Payable - Schedule of Debt (Parenthetical) (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Term Loan Agreement [Member] \| Medium-term Notes [Member]
Debt Instrument
Deferred issuance costs	$ 2.0	$ 1.8

Restricted Cash - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Certificates of deposit [Member]
Restricted Cash And Cash Equivalents Items [Line Items]
Security deposit	$ 0.2	$ 0.2

Leases - Schedule of Other Information Related to Leases (Detail)	Sep. 30, 2019
Leases [Abstract]
Weighted-average remaining lease term - operating leases (in years)	2 years 1 month 6 days
Weighted-average discount rate - operating leases	11.90%